Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | THRA | P10827 | 5/20 | 0.56 |
| ▸ | THRB | P10828 | 5/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27455127 | 0.85 | HSD17B3 (0.67) | HSD17B3THRATHRBSTSHTR7 | |
| SCHEMBL31366289 | 0.85 | HSD17B3 (0.67) | HSD17B3THRATHRBSTSHTR7 | |
| SCHEMBL7758945 | 0.85 | HSD17B3 (0.67) | HSD17B3THRATHRBSTSHTR7 | |
| SCHEMBL15743522 | 0.85 | HSD17B3 (0.67) | HSD17B3THRATHRBSTSHTR7 | |
| SCHEMBL26254861 | 0.85 | HSD17B3 (0.82) | HSD17B3L3MBTL1HPGDSMN1; SMN2STS | |
| SCHEMBL4417711 | 0.83 | HSD17B3 (0.67) | HSD17B3L3MBTL1HPGDSMN1; SMN2THRA | |
| SCHEMBL5270771 | 0.83 | HSD17B3 (0.67) | HSD17B3L3MBTL1HPGDSMN1; SMN2THRA | |
| SCHEMBL508405 | 0.83 | MAPT (0.53) | HSD17B3L3MBTL1SMN1; SMN2THRATHRB | |
| SCHEMBL28908404 | 0.80 | THRA (0.79) | HSD17B3L3MBTL1THRATHRB | |
| SCHEMBL4819030 | 0.80 | CES2 (0.50) | HSD17B3L3MBTL1SMN1; SMN2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637441-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-1828224-B1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX INC (US) | 2016-04-06 | — | — | EP | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8859802-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859802-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8846876-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | Abrx, Inc. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846876-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | Abrx, Inc. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20080177038-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177038-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7385028-B2 | Modified non-natural amino acid polypeptides typically include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group; therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC (US) | 2008-06-10 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332571-B2 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | AMBRX, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177038-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | HSD17B3 4508/4885L3MBTL1 1737/4885HPGD 989/4885 |
| US-20150094457-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | HSD17B3 4466/4885L3MBTL1 2473/4885HPGD 876/4885 |
| US-20080177027-A1 | Non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, therapeutic, diagnostic, and other biotechnology uses | DNPEP, DAO, PTMS | HSD17B3 4508/4885L3MBTL1 1737/4885HPGD 989/4885 |
| US-20080153979-A1 | non-natural amino acids are selected from amino acids having protected or masked carbonyl, dicarbonyl, hydroxylamine, or oxime side chains, and amino acid attached to a polyoxyethylene glycol, acrylic polymers or natural polymer; therapeutic, diagnostic, and other biotechnology uses | DAO, DNPEP, AADAT | HSD17B3 4632/4885L3MBTL1 1362/4885HPGD 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.